SPNT Stock Analysis: Siriuspoint | NYSE
Insurance - Reinsurance | NYSE, USA | Market Cap: 2.895m USD | 12M Return: 26.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 20.4M
EPS Trend: 52.9%
Qual. Beats: 0
Rev. Trend: 66.9%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
SiriusPoint Ltd. is a global multi-line reinsurance and insurance company headquartered in Pembroke, Bermuda, operating through four main segments: Global P&C Programs, Global Reinsurance, Global Accident & Health, and London Market Specialty. Its offerings span casualty, property, aviation and space, marine and energy, credit, surety, and mortgage risks, serving insurance companies, government entities, and other risk-bearing vehicles. The Global Accident & Health segment also provides specialty consumer products such as travel medical insurance, trip cancellation programs, and 24/7 emergency assistance services. The company was originally incorporated in 2011 as Third Point Reinsurance Ltd. and rebranded to SiriusPoint Ltd. in February 2021.
As a Bermuda-domiciled reinsurer, SiriusPoint operates from one of the worlds leading insurance and reinsurance hubs, a jurisdiction that has historically attracted specialty insurers due to its favorable regulatory and tax environment. Reinsurance carriers like SiriusPoint function as a financial buffer for primary insurers, helping them manage catastrophic and large-loss exposures by spreading risk across global capital pools.
- Catastrophe losses pressure Global Reinsurance combined ratio
- Reinsurance pricing hardens at mid-year renewals boosting premium rates
- Investment income surges on higher yields from float portfolio
- Share buyback program accelerates as excess capital returns to shareholders
| Net Income: 500.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 3.26 > 1.0 |
| NWC/Revenue: -23.66% < 20% (prev -59.03%; Δ 35.37% < -1%) |
| CFO/TA 0.03 > 3% & CFO 330.8m > Net Income 500.2m |
| Net Debt (-2.56b) to EBITDA (676.5m): -3.79 < 3 |
| Current Ratio: 0.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (121.8m) vs 12m ago -24.50% < -2% |
| Gross Margin: 45.53% > 18% (prev 26.36%; Δ 19.17% > 0.5%) |
| Asset Turnover: 26.11% > 50% (prev 21.61%; Δ 4.50% > 0%) |
| Interest Coverage Ratio: 8.49 > 6 (EBIT TTM 665.9m / Interest Expense TTM 78.4m) |
| A: -0.06 (Total Current Assets 8.49b - Total Current Liabilities 9.26b) / Total Assets 12.5b |
| B: 0.11 (Retained Earnings 1.33b / Total Assets 12.5b) |
| C: 0.05 (EBIT TTM 665.9m / Avg Total Assets 12.4b) |
| D: 0.23 (Book Value of Equity 2.30b / Total Liabilities 10.2b) |
| Altman-Z'' = 0.54 = B |
As of July 09, 2026, the stock is trading at USD 24.48 with a total of 792,728 shares traded. Over the past week, the price has changed by +2.00%, over one month by +12.04%, over three months by +5.34% and over the past year by +26.77%.
Current recommended Stop Loss: 23.40 (which is 4.4% or 1.6 ATR below the current price).
Siriuspoint has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold SPNT.
- StrongBuy: 0
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 27 | 10.3% |
P/E Trailing = 6.204
P/E Forward = 9.8912
P/S = 0.9555
P/B = 1.2574
Revenue TTM = 3.23b USD
EBIT TTM = 665.9m USD
EBITDA TTM = 676.5m USD
Long Term Debt = 679.6m USD (from longTermDebt, last quarter)
Short Term Debt = 5.10m USD (from shortTermDebt, last quarter)
Debt = 679.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.56b USD (calculated: Debt 679.6m - CCE 3.24b)
Enterprise Value = 333.5m USD (2.90b + Debt 679.6m - CCE 3.24b)
Interest Coverage Ratio = 8.49 (Ebit TTM 665.9m / Interest Expense TTM 78.4m)
EV/FCF = 1.01x (Enterprise Value 333.5m / FCF TTM 330.8m)
FCF Yield = 99.20% (FCF TTM 330.8m / Enterprise Value 333.5m)
FCF Margin = 10.23% (FCF TTM 330.8m / Revenue TTM 3.23b)
Net Margin = 15.47% (Net Income TTM 500.2m / Revenue TTM 3.23b)
Gross Margin = 45.53% ((Revenue TTM 3.23b - Cost of Revenue TTM 1.76b) / Revenue TTM)
Gross Margin QoQ = 53.15% (prev 61.77%)
Tobins Q-Ratio = 0.03 (Enterprise Value 333.5m / Total Assets 12.5b)
Interest Expense / Debt = 11.54% (Interest Expense 78.4m / Debt 679.6m)
Taxrate = 14.83% (87.1m / 587.5m)
NOPAT = 567.2m (EBIT 665.9m * (1 - 14.83%))
Current Ratio = 0.92 (Total Current Assets 8.49b / Total Current Liabilities 9.26b)
Debt / Equity = 0.30 (Debt 679.6m / totalStockholderEquity, last quarter 2.30b)
Debt / EBITDA = -3.79 (Net Debt -2.56b / EBITDA 676.5m)
Debt / FCF = -7.74 (Net Debt -2.56b / FCF TTM 330.8m)
Total Stockholder Equity = 2.27b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.04% (Net Income 500.2m / Total Assets 12.5b)
RoE = 22.02% (Net Income TTM 500.2m / Total Stockholder Equity 2.27b)
RoCE = 22.56% (EBIT 665.9m / Capital Employed (Equity 2.27b + L.T.Debt 679.6m))
RoIC = 18.47% (NOPAT 567.2m / Invested Capital 3.07b)
WACC = 6.80% (E(2.90b)/V(3.57b) * Re(6.09%) + D(679.6m)/V(3.57b) * Rd(11.54%) * (1-Tc(0.15)))
Discount Rate = 6.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -72.17 | Cagr: -14.56%
[DCF] Terminal Value 75.44% ; FCFF base≈330.8m ; Y1≈332.2m ; Y5≈351.9m
[DCF] Fair Price = 68.35 (EV 5.47b - Net Debt -2.56b = Equity 8.03b / Shares 117.5m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: 52.86 | EPS CAGR: 38.24% | SUE: 0.38 | # QB: 0
Revenue Correlation: 66.88 | Revenue CAGR: 5.61% | SUE: -0.03 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.65 | Chg30d=-4.09% | Revisions=-50% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.58 | Chg30d=-1.27% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=2.57 | Chg30d=-0.39% | Revisions=+0% | GrowthEPS=+0.7% | GrowthRev=-2.4%
EPS next Year (2027-12-31): EPS=2.77 | Chg30d=-0.81% | Revisions=-17% | GrowthEPS=+7.7% | GrowthRev=+4.8%
[Analyst] Revisions Ratio: -27% (up=4, down=8)